aldosterone has been researched along with Diabetes Mellitus, Adult-Onset in 161 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective of this study was to evaluate the antihypertensive effect of low dose spironolactone added to triple therapy for resistant hypertension in patients with type 2 diabetes measured by ambulatory monitoring." | 9.17 | Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. ( Gram, J; Henriksen, JE; Jacobsen, IA; Oxlund, CS; Schousboe, K; Tarnow, L, 2013) |
| "The aim was to compare the antiproteinuric effect of aliskiren and ramipril in hypertensive patients with type 2 diabetes and microalbuminuria." | 9.17 | Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2013) |
| "Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months." | 9.14 | Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 9.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)." | 9.08 | Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995) |
| "The finding of adipocyte-derived hormone leptin as an overstimulator of sympathetic activity brought a new perspective to the pathophysiological mechanisms of obesity-hypertension." | 7.78 | Leptin and aldosterone in sympathetic activity in resistant hypertension with or without type 2 diabetes. ( Boer-Martins, L; Demacq, C; Faria, AP; Figueiredo, VN; Martins, LC; Moraes, Cde H; Moreno, H, 2012) |
| "Aldosterone may produce insulin resistance secondarily by altering potassium, increasing inflammatory cytokines, and reducing beneficial adipokines such as adiponectin." | 6.50 | Effects of aldosterone on insulin sensitivity and secretion. ( Luther, JM, 2014) |
| "Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors." | 6.43 | Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. ( Pringle, S; Shah, NC; Struthers, A, 2006) |
| "Primary aldosteronism (PA) due to unilateral aldosterone-producing adenoma (APA) is preferentially treated by unilateral adrenalectomy (ADX), but little is known about the changes in lipid and glucose metabolism that may occur after ADX." | 5.56 | Lipoprotein insulin resistance score and branched-chain amino acids increase after adrenalectomy for unilateral aldosterone-producing adenoma: a preliminary study. ( Adolf, C; Berends, AMA; Connelly, MA; Dullaart, RPF; Reincke, M, 2020) |
| "Considering the role of aldosterone in diabetic nephropathy, genetic polymorphism of this gene may contribute to the development and progression of diabetic nephropathy." | 5.35 | Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients. ( Cha, DR; Kang, YS; Kim, HK; Ko, GJ; Lee, MH; Song, HK, 2008) |
| "Spironolactone reduced albuminuria along with conventional RAS inhibitors in patients with diabetic nephropathy." | 5.20 | Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. ( Ando, M; Araki, H; Goto, M; Imai, E; Kanasaki, K; Kato, S; Kobori, H; Koya, D; Makino, H; Maruyama, S; Matsuo, S; Nishiyama, A; Ogawa, D; Oiso, Y; Uzu, T; Wada, J, 2015) |
| "The aim was to compare the antiproteinuric effect of aliskiren and ramipril in hypertensive patients with type 2 diabetes and microalbuminuria." | 5.17 | Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2013) |
| "The primary objective of this study was to evaluate the antihypertensive effect of low dose spironolactone added to triple therapy for resistant hypertension in patients with type 2 diabetes measured by ambulatory monitoring." | 5.17 | Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. ( Gram, J; Henriksen, JE; Jacobsen, IA; Oxlund, CS; Schousboe, K; Tarnow, L, 2013) |
| "Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months." | 5.14 | Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009) |
| " Subjects with the metabolic syndrome were treated with 0 mg of enalapril (n=9), 5 mg of enalapril (n=8), or 10 mg enalapril (n=7) after treatment with sitagliptin (100 mg/day for 5 days and matching placebo for 5 days) in a randomized, cross-over fashion." | 5.14 | Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. ( Brown, NJ; Byrne, L; Kunchakarra, S; Marney, A, 2010) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 5.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)." | 5.08 | Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995) |
| "Eight normotensive subjects, eight mild-to-moderate hypertensive type II diabetic patients, and eight nondiabetic patients with essential hypertension were studied before and after 4 weeks of being administered enalapril." | 5.07 | Enhanced pressor responsiveness to norepinephrine in type II diabetes. Effect of ACE inhibition. ( Capelli, M; Ciavarella, A; Mustacchio, A; Ricci, C; Vannini, P, 1994) |
| "The finding of adipocyte-derived hormone leptin as an overstimulator of sympathetic activity brought a new perspective to the pathophysiological mechanisms of obesity-hypertension." | 3.78 | Leptin and aldosterone in sympathetic activity in resistant hypertension with or without type 2 diabetes. ( Boer-Martins, L; Demacq, C; Faria, AP; Figueiredo, VN; Martins, LC; Moraes, Cde H; Moreno, H, 2012) |
| " We found that mice with CD knockout of this receptor were resistant to the rosiglitazone- (RGZ) induced increases in body weight and plasma volume expansion found in control mice expressing PPARgamma in the CD." | 3.73 | Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. ( Gonzalez, FJ; Kohan, DE; Nelson, RD; Yang, T; Zhang, A; Zhang, H, 2005) |
| "Hypertension in patients with NIDDM is frequently salt-sensitive, which may be due to sodium retention and enhanced vascular reactivity to angiotensin II." | 3.68 | Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. ( Corry, D; Trujillo, A; Tuck, M, 1990) |
| "Individuals with type 2 diabetes have an increased risk of endothelial dysfunction and cardiovascular disease." | 3.01 | Aldosterone Induces Vasoconstriction in Individuals with Type 2 Diabetes: Effect of Acute Antioxidant Administration. ( Finsen, SH; Hansen, MR; Hansen, PBL; Mortensen, SP, 2021) |
| "After confirmation of Conn's syndrome a differentiation between a unilateral and bilateral adrenal disease is necessary for further treatment planning." | 2.82 | [Conn's syndrome-Frequent and still too rarely diagnosed to underdiagnosed]. ( Adolf, C; Fuss, CT; Hahner, S; Heinrich, DA, 2022) |
| "Aldosterone breakthrough is a frequent event 1 year after initiating renin-angiotensin-aldosterone system blockade, particularly in participants exposed to intensive lowering of BP with sodium depletion and short-acting angiotensin II receptor blockers." | 2.78 | Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. ( Bakris, G; Esnault, VL; Fafin, C; Favre, G; Moranne, O; Pradier, C, 2013) |
| "Aliskiren treatment reduced PRA by 90% at 24 weeks and increased PRC by 328%." | 2.77 | Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. ( Hans-Henrik, P; Hollenberg, NK; Lewis, EJ; Lewis, JB; Persson, F; Rossing, P, 2012) |
| "We enrolled 43 individuals with type 2 diabetes mellitus." | 2.76 | Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? ( Barkoudah, E; Danser, AH; Fisher, ND; Hollenberg, NK; Moukarbel, GV; Nussberger, J, 2011) |
| "Aldosterone is an important pathogenetic factor, independent of the renin-angiotensin system in cardiovascular and renal disease." | 2.73 | Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. ( Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T, 2007) |
| "We studied 30 patients with type 2 diabetes mellitus (mean age 43." | 2.73 | Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. ( Morris, AD; Sharman, DC; Struthers, AD, 2007) |
| "Aldosterone is a steroid hormone that regulates blood pressure and cardiovascular function by acting on renal and vascular mineralocorticoid receptors (MRs) to promote sodium retention and modulate endothelial function." | 2.72 | Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease. ( Jia, G; Lockette, W; Sowers, JR, 2021) |
| "Ultrahigh dosing of irbesartan (900 mg once daily) is generally safe and offers additional renoprotection independent of changes in systemic blood pressure and GFR in comparison to the currently recommended dose of 300 mg." | 2.71 | Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. ( Boomsma, F; Jensen, BR; Parving, HH; Rossing, K; Schjoedt, KJ, 2005) |
| "It has been reported that continuous ACE inhibitor therapy does not necessarily produce a maintained decrease in plasma aldosterone levels, which may remain high or increase eventually during long-term use (aldosterone escape)." | 2.71 | Effectiveness of aldosterone blockade in patients with diabetic nephropathy. ( Hayashi, K; Naruse, M; Saruta, T; Sato, A, 2003) |
| "However, in patients with type 2 diabetes, both with normoalbuminuria and microalbuminuria, RI values after the test were significantly lower than baseline values (P < 0." | 2.71 | Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes: a duplex Doppler sonography study. ( Emoto, M; Hosoi, M; Inaba, M; Ishimura, E; Kawagishi, T; Matsumoto, N; Nakatani, T; Nishizawa, Y; Shoji, S; Shoji, T; Taniwaki, H, 2003) |
| "In both groups, hyperinsulinemia caused a decrease in blood volume (0." | 2.70 | Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. ( Baldi, S; Catalano, C; Ferrannini, E; Nannipieri, M; Prontera, T; Seghieri, G, 2002) |
| "Aldosterone is a key risk factor promoting inflammation and fibrosis causing cardio-renal failure." | 2.66 | Mitigating risk of aldosterone in diabetic kidney disease. ( Frimodt-Møller, M; Persson, F; Rossing, P, 2020) |
| "Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| "Aldosterone may produce insulin resistance secondarily by altering potassium, increasing inflammatory cytokines, and reducing beneficial adipokines such as adiponectin." | 2.50 | Effects of aldosterone on insulin sensitivity and secretion. ( Luther, JM, 2014) |
| "More than 80% of patients with type 2 diabetes mellitus develop hypertension, and approx." | 2.44 | Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. ( Savoia, C; Schiffrin, EL, 2007) |
| "Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors." | 2.43 | Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. ( Pringle, S; Shah, NC; Struthers, A, 2006) |
| "Hypertension is often associated clinically with diabetes as part of the insulin-resistance syndrome or as a manifestation of renal disease." | 2.43 | Hypertension and diabetes: role of the renin-angiotensin system. ( Cooper, ME; Jandeleit-Dahm, K, 2006) |
| "Aldosterone has been assumed to be one of aggravating factors in diabetic kidney disease (DKD)." | 1.91 | Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess. ( Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H, 2023) |
| "Hypertension is common in patients with type 2 diabetes who carry increased cardiovascular risk; however, it is unknown how frequently they are tested for PA." | 1.91 | Screening for primary aldosteronism in the diabetic population: a cohort study. ( Libianto, R; Tan, SJ; Wong, J; Yang, J, 2023) |
| "Aldosterone was not associated with type 2 diabetes (OR: 1." | 1.72 | Association of renin and aldosterone with glucose metabolism in a Western European population: the KORA F4/FF4 study. ( Bidlingmaier, M; Heier, M; Herder, C; Koenig, W; Maalmi, H; Meisinger, C; Meitinger, T; Peters, A; Rathmann, W; Reincke, M; Ritzel, K; Roden, M; Seissler, J; Stumvoll, M; Sujana, C; Then, C; Then, H; Thorand, B, 2022) |
| "Patients were divided into two groups (type 2 diabetes CR and non-CR)." | 1.72 | Preoperative Plasma Aldosterone Predicts Complete Remission of Type 2 Diabetes after Bariatric Surgery. ( Abe, K; Nabekura, T; Nagayama, D; Nakamura, S; Ohira, M; Onda, H; Oshiro, T; Saiki, A; Tanaka, S; Tatsuno, I; Watanabe, Y; Yamaguchi, T; Yamaoka, S, 2022) |
| "Youth with type 2 diabetes (T2D) have high rates of obesity, hypertension and suboptimal glycemic control." | 1.56 | An evaluation of renin-angiotensin system markers in youth with type 2 diabetes and associations with renal outcomes. ( Blydt-Hansen, T; Burns, K; Dart, AB; Dyck, J; Hamilton, J; Mahmud, F; Scholey, J; Sellers, EA; Sochett, E; Wicklow, B, 2020) |
| "Primary aldosteronism (PA) due to unilateral aldosterone-producing adenoma (APA) is preferentially treated by unilateral adrenalectomy (ADX), but little is known about the changes in lipid and glucose metabolism that may occur after ADX." | 1.56 | Lipoprotein insulin resistance score and branched-chain amino acids increase after adrenalectomy for unilateral aldosterone-producing adenoma: a preliminary study. ( Adolf, C; Berends, AMA; Connelly, MA; Dullaart, RPF; Reincke, M, 2020) |
| "05), with a nonlinear dose-response trend, but the association between 11-deoxycorticosterone and T2DM was no statistical significance after adjustment." | 1.56 | Mineralocorticoids, glucose homeostasis and type 2 diabetes mellitus: The Henan Rural Cohort study. ( Fan, M; Hou, J; Huo, W; Jiang, J; Li, L; Li, R; Liu, X; Mao, Z; Qiao, D; Tu, R; Wang, C; Wang, Y; Wei, D; Yang, X; Yu, S; Zhang, J, 2020) |
| "Aldosterone has been proved a risk factor of fibrosis and inflammation." | 1.51 | Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D. ( Chen, L; Cui, C; Guo, X; He, Q; Hou, X; Hu, H; Liu, F; Qin, J; Song, J; Wang, J; Yan, F, 2019) |
| "Patients with type 2 diabetes mellitus (DM) exhibit modification of high-density lipoprotein (HDL), which is likely to have an important role in the development of atherosclerotic cardiovascular disease (ASCVD)." | 1.46 | Advanced glycation of high-density lipoprotein and the functionality of aldosterone release in type 2 diabetes. ( Arimura, T; Imaizumi, S; Kuwano, T; Matsuo, Y; Miura, SI; Nakayama, A; Norimatsu, K; Saku, K; Shiga, Y; Tomita, S, 2017) |
| "Obesity and type 2 diabetes have become a major public health problem worldwide." | 1.46 | Elevated Steroid Hormone Production in the db/db Mouse Model of Obesity and Type 2 Diabetes. ( Bornstein, SR; Brown, N; Brunssen, C; Eisenhofer, G; Frenzel, A; Hofmann, A; Jannasch, A; Mittag, J; Morawietz, H; Peitzsch, M; Weldon, SM, 2017) |
| "were enrolled individuals with type 2 diabetes between February 2008 and December 2013." | 1.46 | Prevalence of primary aldosteronism among patients with type 2 diabetes. ( Dahlqvist, S; Eggertsen, R; Eliasson, B; Imberg, H; Johannsson, G; Lind, M; Lindblad, U; Tancredi, M, 2017) |
| "Dapagliflozin treatment showed beneficial effects on diabetic nephropathy, which might be via suppression of renal RAS component expression, oxidative stress and interstitial fibrosis in OLETF rats." | 1.43 | Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. ( Ahn, YB; Chung, S; Kim, ES; Kim, JW; Kim, MJ; Kim, SJ; Ko, SH; Lee, EM; Moon, SD; Shin, SJ; Yoo, YH, 2016) |
| " The aim of this study was to investigate whether or not the effect of β-blocker therapy on the ARR could be predicted from the dosing regimen." | 1.43 | A cross-sectional study of the effects of β-blocker therapy on the interpretation of the aldosterone/renin ratio: can dosing regimen predict effect? ( Browne, GA; Dennedy, MC; Griffin, TP; OʼShea, PM; Wall, D, 2016) |
| "Plasma aldosterone is elevated in type 2 diabetes and obesity in experimental and clinical studies and can act to inhibit both glucose-stimulated insulin secretion by the β-cell and insulin signaling." | 1.43 | Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats. ( Bornstein, SR; Brown, NF; Brunssen, C; Deussen, A; Eisenhofer, G; Engelmann, F; Hofmann, A; Huber, J; Jannasch, A; Martin, M; Mittag, J; Morawietz, H; Peitzsch, M; Streicher, R; Weldon, SM, 2016) |
| "Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years." | 1.42 | Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up. ( Bailey, KR; Buglioni, A; Burnett, JC; Cannone, V; Heublein, DM; Rodeheffer, RJ; Sangaralingham, SJ; Sarzani, R; Scott, CG, 2015) |
| "Spironolactone treatment did not affect blood pressure, fasting glucose levels or weight gain, but increased serum potassium and total cholesterol in both, diabetic and control mice." | 1.42 | Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus. ( Bruder-Nascimento, T; Cau, SB; Lopes, RA; Manzato, CP; Mestriner, FL; Montezano, AC; Neves, KB; Nguyen Dinh Cat, A; Silva, MA; Tostes, RC; Touyz, RM, 2015) |
| "sPRR in patients with primary aldosteronism (low renin-low prorenin) and Gitelman syndrome (high renin-high prorenin) were similar and ≈10% higher than in healthy subjects." | 1.40 | Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldosterone concentrations but is affected by ethnicity. ( Azizi, M; Baron, S; Bergerot, D; Blanchard, A; Caumont-Prim, A; Chambon, Y; Curis, E; Frank, M; Hirose, T; Nguyen, G; Tabard, SB; Totsune, K, 2014) |
| "In 33 hypertensive patients with type 2 diabetes mellitus treated with a calcium channel blocker other than cilnidipine, we evaluated the influence of switching to cilnidipine on blood pressure, heart rate, catecholamine, plasma renin and aldosterone concentration, brain natriuretic peptide, urine liver-type fatty acid binding protein, and urinary albumin excretion ratio in the same patients by a cross-over design." | 1.40 | Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels. ( Ichihara, A; Itoh, H; Nishimura, T; Sekioka, R; Tanaka, M, 2014) |
| "Humans with obesity and type 2 diabetes and KKAy and db/db mice were used to evaluate SGK1 expression in the adipose tissue of subjects with obesity and diabetes using quantitative real-time PCR and Western blot analysis." | 1.39 | SGK1 is regulated by metabolic-related factors in 3T3-L1 adipocytes and overexpressed in the adipose tissue of subjects with obesity and diabetes. ( Feng, W; Hao, Y; Li, P; Pan, F; Song, H; Zhu, D, 2013) |
| "Aldosterone treatment impaired the rate of glucose uptake, oxidation, and insulin signal transduction in the gastrocnemius muscle through defective expression of IR, IRS-1, Akt, AS160, and GLUT4 genes." | 1.39 | Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat. ( Balasubramanian, K; Mayilvanan, C; Sathish, S; Selvaraj, J, 2013) |
| "Patients with type 2 diabetes mellitus without evidence of coronary artery disease were recruited." | 1.39 | Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus. ( Abbasi, SA; Adler, GK; Di Carli, MF; Garg, R; Jerosch-Herold, M; Kwong, RY; Neilan, TG; Perlstein, TS; Rao, AD; Shah, RV, 2013) |
| "Hypertension is a frequent complication of type 2 diabetes mellitus (DM) because of the close etiological relationship between these two diseases." | 1.39 | Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. ( Akehi, Y; Murase, K; Nagaishi, R; Nomiyama, T; Takenoshita, H; Yanase, T, 2013) |
| "Patients with type 2 diabetes (T2D) manifest significant abnormalities in lipoprotein structure and function." | 1.38 | Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways. ( Bornstein, SR; Goettsch, C; Graessler, J; Kopprasch, S; Saha, S; Schwarz, PE, 2012) |
| "She was diagnosed with combined primary hyperaldosteronism and Cushing's syndrome." | 1.38 | Combined aldosterone and cortisol secretion by adrenal incidentaloma. ( di Dalmazi, G; Giampalma, E; Golfieri, R; Marrano, N; Minni, F; Pasquali, R; Repaci, A; Rinaldi, E; Santini, D; Vicennati, V, 2012) |
| "Aldosterone levels were also correlated with 24-h pulse pressure (rho = -0." | 1.37 | Relationships between renin, aldosterone, and 24-hour ambulatory blood pressure in obese adolescents. ( Flynn, JT; Shatat, IF, 2011) |
| "Insulin resistance was calculated using the homeostasis model assessment (HOMA-IR)." | 1.37 | Cardiovascular correlates of insulin resistance in normotensive and hypertensive African Americans. ( Grim, CE; Kidambi, S; Kotchen, JM; Kotchen, TA; Krishnaswami, S, 2011) |
| "Thus, in insulin-resistant type 2 diabetes (T2D), oxidative stress generated by hyperglycemia and aldosterone would potentiate the oxidative destruction of tissue and important regulators of glucose metabolism like adiponectin and insulin." | 1.35 | The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. ( Jadhav, A; Lane, N; Ndisang, JF, 2009) |
| "Aldosterone is an important mediator of cardiovascular and renal remodeling." | 1.35 | Increased aldosterone levels in a model of type 2 diabetes mellitus. ( Birner, C; Endemann, DH; Fredersdorf, S; Heitzmann, D; Luchner, A; Muders, F; Resch, M; Riegger, GA; Schmid, P; Stoelcker, B; Ulucan, C; Weil, J, 2009) |
| "Considering the role of aldosterone in diabetic nephropathy, genetic polymorphism of this gene may contribute to the development and progression of diabetic nephropathy." | 1.35 | Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients. ( Cha, DR; Kang, YS; Kim, HK; Ko, GJ; Lee, MH; Song, HK, 2008) |
| "The GK rats developed hypertension, cardiac hypertrophy and overexpression of cardiac natriuretic peptides and profibrotic connective tissue growth factor compared to nondiabetic Wistar rats." | 1.33 | Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. ( Bäcklund, T; Cheng, ZJ; Eriksson, A; Finckenberg, P; Grönholm, T; Laine, M; Mervaala, E; Palojoki, E; Tikkanen, I; Vuolteenaho, O, 2005) |
| "Spironolactone treatment did not induce any significant change in blood glucose levels and blood pressure." | 1.33 | Role of aldosterone in diabetic nephropathy. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, HK; Kim, YS, 2005) |
| "Spironolactone treatment did not induce any significant differences in body weight, kidney/body weight ratio, serum creatinine concentration, blood glucose levels, or systolic blood pressure." | 1.33 | Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, HK; Kim, YS; Lee, MH, 2006) |
| "We present a patient with Type 2 diabetes and previously undiagnosed hyperaldosteronism who developed life-threatening hypokalaemia while following a low-carbohydrate diet." | 1.33 | Life-threatening hypokalaemia on a low-carbohydrate diet associated with previously undiagnosed primary hyperaldosteronism [corrected]. ( Advani, A; Taylor, R, 2005) |
| "We examined 32 patients, 11 type 2 diabetes mellitus and 21 non-diabetic patients, with atherosclerotic epicardial arteries free of significant luminal stenoses." | 1.33 | Impaired effect of endothelin-1 on coronary artery stiffness in type 2 diabetes. ( Johnston, N; Kremastinos, DT; Kyriakides, ZS; Kyrzopoulos, S; Raptis, AE; Raptis, SA; Sbarouni, E; Webb, DJ, 2006) |
| "We evaluated the renal hemodynamic status of 19 hypertensive patients with NIDDM under controlled sodium balance, low (10 mmol/day for 5 to 7 days) or high (200 mmol/day for 5 to 7 days)." | 1.30 | Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. ( Allan, DR; De'Oliveira, JM; Fisher, ND; Hollenberg, NK; McKnight, JA; Price, DA; Williams, GH, 1997) |
| "Patients who have Type II diabetes mellitus and orthostatic hypotension are hypovolemic and have sympathoadrenal insufficiency; both factors contribute to the pathogenesis of orthostatic hypotension." | 1.30 | Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus. ( Ferrari, P; Laederach-Hofmann, K; Weidmann, P, 1999) |
| "1." | 1.29 | Acute sodium loading in patients with uncomplicated diabetes mellitus: renal and hormonal effects. ( Beretta-Piccoli, C; Cusi, D; Elshater-Zanetti, F; Shaw, S; Weidmann, P, 1994) |
| "Subjects with Type 2 diabetes have been reported to have elevated total exchangeable sodium when compared with normal subjects." | 1.28 | Basal and stimulated plasma atrial natriuretic factor in type 2 diabetes. ( Atkinson, AB; McKnight, JA; Roberts, G; Sheridan, B, 1991) |
| "Presence of moderately advanced diabetic nephropathy and autonomic neuropathy influenced only slightly WI induced alterations of the renin-aldosterone system and AVP secretion." | 1.27 | [Effect of water immersion on plasma renin activity, vasopressin and aldosterone level in diabetics]. ( Duława, J; Grzeszczak, W; Kokot, F; Wiecek, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (5.59) | 18.7374 |
| 1990's | 24 (14.91) | 18.2507 |
| 2000's | 42 (26.09) | 29.6817 |
| 2010's | 55 (34.16) | 24.3611 |
| 2020's | 31 (19.25) | 2.80 |
| Authors | Studies |
|---|---|
| Greco, EA | 1 |
| Feraco, A | 1 |
| Marzolla, V | 1 |
| Mirabelli, M | 1 |
| Cimino, L | 1 |
| Armani, A | 1 |
| Brunetti, A | 1 |
| Caprio, M | 1 |
| Memon, SS | 1 |
| Lila, A | 1 |
| Barnabas, R | 1 |
| Goroshi, M | 1 |
| Sarathi, V | 1 |
| Shivane, V | 1 |
| Patil, V | 1 |
| Shah, N | 1 |
| Bandgar, T | 1 |
| Higashikawa, T | 1 |
| Ito, T | 2 |
| Mizuno, T | 1 |
| Ishigami, K | 1 |
| Kuroki, K | 1 |
| Maekawa, N | 1 |
| Usuda, D | 1 |
| Morita, T | 1 |
| Hamada, K | 1 |
| Takagi, S | 1 |
| Takeshima, K | 1 |
| Yamada, S | 1 |
| Sangen, R | 1 |
| Izumida, T | 1 |
| Mori, H | 1 |
| Kiyosawa, J | 1 |
| Saito, A | 1 |
| Iguchi, M | 1 |
| Nakahashi, T | 1 |
| Kasamaki, Y | 1 |
| Fukuda, A | 1 |
| Kanda, T | 1 |
| Okuro, M | 1 |
| Fuss, CT | 2 |
| Hahner, S | 1 |
| Heinrich, DA | 1 |
| Adolf, C | 2 |
| Tan, SJ | 1 |
| Libianto, R | 3 |
| Yang, J | 1 |
| Wong, J | 1 |
| Ohira, M | 1 |
| Abe, K | 1 |
| Yamaguchi, T | 2 |
| Onda, H | 1 |
| Yamaoka, S | 1 |
| Nakamura, S | 1 |
| Tanaka, S | 1 |
| Watanabe, Y | 1 |
| Nabekura, T | 1 |
| Oshiro, T | 1 |
| Nagayama, D | 2 |
| Saiki, A | 2 |
| Tatsuno, I | 1 |
| Then, C | 2 |
| Ritzel, K | 1 |
| Herder, C | 1 |
| Then, H | 1 |
| Sujana, C | 1 |
| Heier, M | 2 |
| Meisinger, C | 2 |
| Peters, A | 2 |
| Koenig, W | 2 |
| Rathmann, W | 2 |
| Roden, M | 1 |
| Maalmi, H | 1 |
| Stumvoll, M | 1 |
| Meitinger, T | 1 |
| Bidlingmaier, M | 2 |
| Seissler, J | 2 |
| Thorand, B | 1 |
| Reincke, M | 4 |
| Vukajlovic, T | 1 |
| Sailer, CO | 1 |
| Asmar, A | 1 |
| Jensen, BL | 1 |
| Vogt, DR | 1 |
| Christ-Crain, M | 1 |
| Winzeler, B | 1 |
| Higa, M | 1 |
| Ichijo, T | 1 |
| Hirose, T | 2 |
| Spyroglou, A | 1 |
| Handgriff, L | 1 |
| Müller, L | 1 |
| Schwarzlmüller, P | 1 |
| Parasiliti-Caprino, M | 1 |
| Remde, H | 1 |
| Hirsch, A | 1 |
| O'Toole, SM | 1 |
| Thuzar, M | 1 |
| Petramala, L | 1 |
| Letizia, C | 1 |
| Deflorenne, E | 1 |
| Amar, L | 1 |
| Vrckovnik, R | 1 |
| Kocjan, T | 1 |
| Zhang, CD | 1 |
| Li, D | 1 |
| Singh, S | 1 |
| Katabami, T | 1 |
| Yoneda, T | 3 |
| Murakami, M | 1 |
| Wada, N | 1 |
| Inagaki, N | 1 |
| Quinkler, M | 1 |
| Ghigo, E | 1 |
| Maccario, M | 1 |
| Stowasser, M | 1 |
| Drake, WM | 1 |
| Fassnacht, M | 1 |
| Bancos, I | 1 |
| Naruse, M | 2 |
| Beuschlein, F | 1 |
| Epstein, M | 1 |
| Kovesdy, CP | 1 |
| Clase, CM | 1 |
| Sood, MM | 1 |
| Pecoits-Filho, R | 1 |
| Manosroi, W | 3 |
| Danpanichkul, P | 3 |
| Atthakomol, P | 3 |
| Hegyi, B | 3 |
| Mira Hernandez, J | 3 |
| Ko, CY | 3 |
| Hong, J | 3 |
| Shen, EY | 3 |
| Spencer, ER | 3 |
| Smoliarchuk, D | 3 |
| Navedo, MF | 3 |
| Bers, DM | 3 |
| Bossuyt, J | 3 |
| Renke, G | 1 |
| Starling-Soares, B | 1 |
| Baesso, T | 1 |
| Petronio, R | 1 |
| Aguiar, D | 1 |
| Paes, R | 1 |
| Amin, M | 1 |
| Perrelli, M | 1 |
| Wu, R | 1 |
| Gragnoli, C | 1 |
| Nishio, H | 1 |
| Ishii, A | 1 |
| Yamada, H | 1 |
| Mori, KP | 1 |
| Kato, Y | 1 |
| Ohno, S | 1 |
| Handa, T | 1 |
| Sugioka, S | 1 |
| Ishimura, T | 1 |
| Ikushima, A | 1 |
| Inoue, Y | 1 |
| Minamino, N | 1 |
| Mukoyama, M | 1 |
| Yanagita, M | 1 |
| Yokoi, H | 1 |
| Dattani, R | 1 |
| Ul-Haq, Z | 1 |
| Shah, M | 1 |
| Goldet, G | 1 |
| Darzi, LA | 1 |
| Ashrafian, H | 1 |
| Kamalati, T | 1 |
| Frankel, AH | 1 |
| Tam, FWK | 1 |
| Chinnadurai, R | 1 |
| Rengarajan, S | 1 |
| Budden, JJ | 1 |
| Quinn, CM | 1 |
| Kalra, PA | 1 |
| Anno, T | 1 |
| Mune, T | 1 |
| Takai, M | 1 |
| Kimura, T | 1 |
| Hirukawa, H | 1 |
| Kawasaki, F | 1 |
| Okimoto, N | 1 |
| Kaku, K | 1 |
| Kaneto, H | 1 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Zhang, Z | 2 |
| Yan, K | 1 |
| Li, C | 2 |
| Li, Y | 4 |
| Li, L | 4 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Li, J | 5 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 2 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 1 |
| Feng, C | 1 |
| Wang, Z | 1 |
| Wang, Y | 5 |
| Hu, X | 1 |
| Li, Z | 2 |
| Shen, Y | 1 |
| Hu, D | 1 |
| Chen, H | 1 |
| Wu, X | 1 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 1 |
| Zhang, X | 2 |
| Yang, X | 3 |
| Zhang, J | 5 |
| Wang, H | 1 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 3 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 1 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Meng, Y | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Wang, J | 3 |
| Geng, Y | 1 |
| Zhang, Y | 3 |
| Wang, X | 3 |
| Liu, J | 2 |
| Basit, A | 1 |
| Miao, T | 1 |
| Liu, W | 2 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Li, S | 1 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 1 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 1 |
| Wang, C | 2 |
| Zhao, W | 1 |
| Xia, X | 1 |
| Jiang, Y | 1 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 1 |
| Chen, X | 2 |
| Mo, J | 1 |
| Zhang, S | 2 |
| Li, X | 1 |
| Huang, T | 1 |
| Zhu, Q | 1 |
| Wang, S | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 2 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 1 |
| Frew, R | 1 |
| Guo, X | 2 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Zhang, M | 1 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Xiao, J | 1 |
| Song, M | 1 |
| Chen, C | 1 |
| Huang, Q | 1 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 1 |
| Zhang, W | 1 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 1 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 2 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 2 |
| Wang, B | 1 |
| Xie, S | 1 |
| Deng, W | 1 |
| Wu, D | 1 |
| Zhang, Q | 1 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 2 |
| Xu, C | 1 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Tian, L | 1 |
| Guo, L | 1 |
| Chen, AX | 1 |
| Moran, JL | 1 |
| Baqar, S | 2 |
| O'Callaghan, C | 1 |
| MacIsaac, RJ | 2 |
| Jerums, G | 3 |
| Ekinci, EI | 2 |
| Frimodt-Møller, M | 1 |
| Persson, F | 2 |
| Rossing, P | 2 |
| Wei, D | 1 |
| Liu, X | 1 |
| Jiang, J | 1 |
| Tu, R | 1 |
| Qiao, D | 1 |
| Li, R | 1 |
| Fan, M | 1 |
| Hou, J | 1 |
| Huo, W | 1 |
| Yu, S | 1 |
| Mao, Z | 1 |
| Berends, AMA | 1 |
| Connelly, MA | 1 |
| Dullaart, RPF | 1 |
| Hu, Y | 1 |
| Su, X | 1 |
| Bornstein, SR | 5 |
| Dalan, R | 1 |
| Hopkins, D | 1 |
| Mingrone, G | 1 |
| Boehm, BO | 1 |
| Isshiki, M | 1 |
| Sakuma, I | 1 |
| Hayashino, Y | 1 |
| Sumita, T | 1 |
| Hara, K | 1 |
| Takahashi, K | 1 |
| Shiojima, I | 1 |
| Satoh-Asahara, N | 1 |
| Kitazato, H | 1 |
| Ito, D | 1 |
| Saito, D | 1 |
| Hatano, M | 1 |
| Ikegami, Y | 1 |
| Iida, S | 1 |
| Shimada, A | 1 |
| Noda, M | 1 |
| Dart, AB | 1 |
| Wicklow, B | 1 |
| Scholey, J | 1 |
| Sellers, EA | 1 |
| Dyck, J | 1 |
| Mahmud, F | 1 |
| Sochett, E | 1 |
| Hamilton, J | 1 |
| Blydt-Hansen, T | 1 |
| Burns, K | 1 |
| Sydorchuk, L | 1 |
| Dzhuryak, V | 1 |
| Sydorchuk, A | 1 |
| Levytska, S | 1 |
| Petrynych, V | 1 |
| Knut, R | 1 |
| Kshanovska, A | 1 |
| Iftoda, O | 1 |
| Tkachuk, O | 1 |
| Kyfiak, P | 1 |
| Popovich, A | 1 |
| Khomko, O | 1 |
| Sydorchuk, R | 1 |
| Finsen, SH | 1 |
| Hansen, MR | 1 |
| Hansen, PBL | 1 |
| Mortensen, SP | 1 |
| Sawamura, T | 1 |
| Karashima, S | 2 |
| Nagase, S | 1 |
| Nambo, H | 1 |
| Shimizu, E | 1 |
| Higashitani, T | 1 |
| Aono, D | 1 |
| Ohbatake, A | 1 |
| Kometani, M | 1 |
| Demura, M | 1 |
| Furukawa, K | 1 |
| Takeda, Y | 2 |
| Patrono, C | 1 |
| Volpe, M | 1 |
| Jia, G | 1 |
| Lockette, W | 1 |
| Sowers, JR | 3 |
| Tancredi, M | 1 |
| Johannsson, G | 1 |
| Eliasson, B | 1 |
| Eggertsen, R | 1 |
| Lindblad, U | 1 |
| Dahlqvist, S | 1 |
| Imberg, H | 1 |
| Lind, M | 1 |
| Griffin, TP | 3 |
| Wall, D | 2 |
| Browne, GA | 2 |
| Dennedy, MC | 2 |
| O'Shea, PM | 2 |
| Joseph, JJ | 2 |
| Echouffo Tcheugui, JB | 1 |
| Effoe, VS | 2 |
| Hsueh, WA | 1 |
| Allison, MA | 1 |
| Golden, SH | 2 |
| Islam, MN | 1 |
| Blake, L | 1 |
| Bell, M | 1 |
| Griffin, MD | 1 |
| Lytvyn, Y | 1 |
| Godoy, LC | 1 |
| Scholtes, RA | 1 |
| van Raalte, DH | 1 |
| Cherney, DZ | 1 |
| Hu, H | 1 |
| Yan, F | 1 |
| Qin, J | 1 |
| Cui, C | 1 |
| He, Q | 1 |
| Hou, X | 1 |
| Liu, F | 1 |
| Chen, L | 1 |
| Fogari, R | 1 |
| Mugellini, A | 1 |
| Zoppi, A | 1 |
| Preti, P | 1 |
| Maffioli, P | 1 |
| Perrone, T | 1 |
| Derosa, G | 1 |
| Rao, AD | 1 |
| Shah, RV | 1 |
| Garg, R | 1 |
| Abbasi, SA | 1 |
| Neilan, TG | 1 |
| Perlstein, TS | 1 |
| Di Carli, MF | 1 |
| Jerosch-Herold, M | 1 |
| Kwong, RY | 1 |
| Adler, GK | 1 |
| Murase, K | 1 |
| Nagaishi, R | 1 |
| Takenoshita, H | 1 |
| Nomiyama, T | 1 |
| Akehi, Y | 1 |
| Yanase, T | 1 |
| Zhou, R | 1 |
| Lin, ZH | 1 |
| Jiang, CS | 1 |
| Gong, JX | 1 |
| Chen, LL | 1 |
| Guo, YW | 1 |
| Lam, Q | 1 |
| Chen, A | 1 |
| Pyrlis, F | 1 |
| Moran, J | 1 |
| Moranne, O | 1 |
| Bakris, G | 1 |
| Fafin, C | 1 |
| Favre, G | 1 |
| Pradier, C | 1 |
| Esnault, VL | 1 |
| Navaneethan, SD | 1 |
| Bravo, EL | 1 |
| Li, P | 1 |
| Pan, F | 1 |
| Hao, Y | 1 |
| Feng, W | 1 |
| Oxlund, CS | 1 |
| Henriksen, JE | 1 |
| Tarnow, L | 1 |
| Schousboe, K | 1 |
| Gram, J | 1 |
| Jacobsen, IA | 1 |
| Fernández-Juárez, G | 1 |
| Luño, J | 1 |
| Barrio, V | 1 |
| de Vinuesa, SG | 1 |
| Praga, M | 1 |
| Goicoechea, M | 1 |
| Lahera, V | 1 |
| Casas, L | 1 |
| Oliva, J | 1 |
| Nguyen, G | 1 |
| Blanchard, A | 1 |
| Curis, E | 1 |
| Bergerot, D | 1 |
| Chambon, Y | 1 |
| Caumont-Prim, A | 1 |
| Tabard, SB | 1 |
| Baron, S | 1 |
| Frank, M | 1 |
| Totsune, K | 1 |
| Azizi, M | 1 |
| Fazal, L | 1 |
| Azibani, F | 1 |
| Bihry, N | 1 |
| Coutance, G | 1 |
| Polidano, E | 1 |
| Merval, R | 1 |
| Vodovar, N | 1 |
| Launay, JM | 1 |
| Delcayre, C | 1 |
| Samuel, JL | 1 |
| Luther, JM | 1 |
| Abe, M | 3 |
| Oikawa, O | 1 |
| Okada, K | 3 |
| Soma, M | 3 |
| Tanaka, M | 1 |
| Sekioka, R | 1 |
| Nishimura, T | 1 |
| Ichihara, A | 1 |
| Itoh, H | 1 |
| Kato, S | 1 |
| Maruyama, S | 1 |
| Makino, H | 1 |
| Wada, J | 1 |
| Ogawa, D | 1 |
| Uzu, T | 1 |
| Araki, H | 1 |
| Koya, D | 1 |
| Kanasaki, K | 1 |
| Oiso, Y | 1 |
| Goto, M | 1 |
| Nishiyama, A | 1 |
| Kobori, H | 1 |
| Imai, E | 1 |
| Ando, M | 1 |
| Matsuo, S | 1 |
| Amin, NB | 1 |
| Mitchell, JR | 1 |
| Lee, DS | 1 |
| Nucci, G | 1 |
| Rusnak, JM | 1 |
| Silva, MA | 1 |
| Cau, SB | 1 |
| Lopes, RA | 1 |
| Manzato, CP | 1 |
| Neves, KB | 1 |
| Bruder-Nascimento, T | 1 |
| Mestriner, FL | 1 |
| Montezano, AC | 1 |
| Nguyen Dinh Cat, A | 1 |
| Touyz, RM | 1 |
| Tostes, RC | 1 |
| Buglioni, A | 1 |
| Cannone, V | 1 |
| Sangaralingham, SJ | 1 |
| Heublein, DM | 1 |
| Scott, CG | 1 |
| Bailey, KR | 1 |
| Rodeheffer, RJ | 1 |
| Sarzani, R | 1 |
| Burnett, JC | 1 |
| OʼShea, PM | 1 |
| Zavatta, G | 1 |
| Casadio, E | 1 |
| Rinaldi, E | 2 |
| Pagotto, U | 1 |
| Pasquali, R | 2 |
| Vicennati, V | 2 |
| Echouffo-Tcheugui, JB | 1 |
| Kalyani, RR | 1 |
| Yeh, HC | 2 |
| Bertoni, AG | 1 |
| Casanova, R | 1 |
| Sims, M | 1 |
| Correa, A | 2 |
| Wu, WC | 1 |
| Wand, GS | 1 |
| Rottenkolber, M | 1 |
| Lechner, A | 1 |
| Hofmann, A | 2 |
| Brunssen, C | 2 |
| Peitzsch, M | 2 |
| Martin, M | 1 |
| Mittag, J | 2 |
| Jannasch, A | 2 |
| Engelmann, F | 1 |
| Brown, NF | 1 |
| Weldon, SM | 2 |
| Huber, J | 1 |
| Streicher, R | 1 |
| Deussen, A | 1 |
| Eisenhofer, G | 2 |
| Morawietz, H | 2 |
| Kuwano, T | 1 |
| Miura, SI | 1 |
| Norimatsu, K | 1 |
| Arimura, T | 1 |
| Shiga, Y | 1 |
| Tomita, S | 1 |
| Nakayama, A | 1 |
| Matsuo, Y | 1 |
| Imaizumi, S | 1 |
| Saku, K | 1 |
| Shin, SJ | 1 |
| Chung, S | 1 |
| Kim, SJ | 1 |
| Lee, EM | 1 |
| Yoo, YH | 1 |
| Kim, JW | 1 |
| Ahn, YB | 1 |
| Kim, ES | 1 |
| Moon, SD | 1 |
| Kim, MJ | 1 |
| Ko, SH | 1 |
| Frenzel, A | 1 |
| Brown, N | 1 |
| Chatterjee, R | 1 |
| Davenport, CA | 1 |
| Svetkey, LP | 1 |
| Batch, BC | 1 |
| Lin, PH | 1 |
| Ramachandran, VS | 1 |
| Fox, ER | 1 |
| Harman, J | 1 |
| Selvin, E | 1 |
| Butler, K | 1 |
| Edelman, D | 1 |
| Fredersdorf, S | 2 |
| Endemann, DH | 2 |
| Luchner, A | 2 |
| Heitzmann, D | 1 |
| Ulucan, C | 1 |
| Birner, C | 1 |
| Schmid, P | 1 |
| Stoelcker, B | 1 |
| Resch, M | 2 |
| Muders, F | 1 |
| Riegger, GA | 2 |
| Weil, J | 2 |
| Ko, GJ | 1 |
| Kang, YS | 3 |
| Lee, MH | 2 |
| Song, HK | 1 |
| Kim, HK | 3 |
| Cha, DR | 3 |
| Kopprasch, S | 2 |
| Pietzsch, J | 1 |
| Ansurudeen, I | 1 |
| Graessler, J | 2 |
| Krug, AW | 1 |
| Ehrhart-Bornstein, M | 1 |
| Umpierrez, GE | 1 |
| Smiley, D | 1 |
| Robalino, G | 1 |
| Peng, L | 1 |
| Kitabchi, AE | 1 |
| Khan, B | 1 |
| Le, A | 1 |
| Quyyumi, A | 1 |
| Brown, V | 1 |
| Phillips, LS | 1 |
| Ndisang, JF | 1 |
| Lane, N | 1 |
| Jadhav, A | 1 |
| Hayashi, T | 1 |
| Takai, S | 1 |
| Yamashita, C | 1 |
| Sasaki, H | 1 |
| Endo, K | 1 |
| Ban, N | 1 |
| Kawana, H | 1 |
| Ohhira, M | 1 |
| Oyama, T | 1 |
| Miyashita, Y | 1 |
| Shirai, K | 1 |
| de Boer, RA | 1 |
| Martens, FM | 1 |
| Kuipers, I | 1 |
| Boomsma, F | 2 |
| Visseren, FL | 1 |
| Bergler, T | 1 |
| Griese, DP | 1 |
| Kreuzer, P | 1 |
| Brunner, S | 1 |
| Marney, A | 1 |
| Kunchakarra, S | 1 |
| Byrne, L | 1 |
| Brown, NJ | 1 |
| Kidambi, S | 1 |
| Kotchen, JM | 1 |
| Krishnaswami, S | 1 |
| Grim, CE | 1 |
| Kotchen, TA | 1 |
| Putintsev, AM | 1 |
| Shraer, TI | 1 |
| Sergeev, VN | 1 |
| Maslov, MG | 1 |
| Strukova, OA | 1 |
| Shatat, IF | 1 |
| Flynn, JT | 1 |
| Ott, C | 1 |
| Schneider, MP | 1 |
| Delles, C | 1 |
| Schlaich, MP | 1 |
| Hilgers, KF | 1 |
| Schmieder, RE | 1 |
| Maruyama, N | 2 |
| Matsumoto, S | 1 |
| Matsumoto, K | 1 |
| Lewis, JB | 1 |
| Lewis, EJ | 1 |
| Hollenberg, NK | 5 |
| Hans-Henrik, P | 1 |
| Fisher, ND | 4 |
| Nussberger, J | 1 |
| Moukarbel, GV | 1 |
| Barkoudah, E | 1 |
| Danser, AH | 1 |
| Repaci, A | 1 |
| di Dalmazi, G | 1 |
| Golfieri, R | 1 |
| Giampalma, E | 1 |
| Minni, F | 1 |
| Marrano, N | 1 |
| Santini, D | 1 |
| Saha, S | 1 |
| Schwarz, PE | 1 |
| Goettsch, C | 1 |
| Suzuki, H | 1 |
| Fujii, Y | 1 |
| Ito, M | 1 |
| Yoshida, Y | 1 |
| Boer-Martins, L | 1 |
| Figueiredo, VN | 1 |
| Demacq, C | 1 |
| Martins, LC | 1 |
| Faria, AP | 1 |
| Moraes, Cde H | 1 |
| Moreno, H | 1 |
| Selvaraj, J | 1 |
| Sathish, S | 1 |
| Mayilvanan, C | 1 |
| Balasubramanian, K | 1 |
| Fouad, AA | 1 |
| Al-Mulhim, AS | 1 |
| Jresat, I | 1 |
| Morsy, MA | 1 |
| Bender, SB | 1 |
| McGraw, AP | 1 |
| Jaffe, IZ | 1 |
| Taniwaki, H | 1 |
| Ishimura, E | 1 |
| Kawagishi, T | 1 |
| Matsumoto, N | 1 |
| Hosoi, M | 1 |
| Emoto, M | 1 |
| Shoji, T | 1 |
| Shoji, S | 1 |
| Nakatani, T | 1 |
| Inaba, M | 1 |
| Nishizawa, Y | 1 |
| Sato, A | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Davies, J | 2 |
| Struthers, A | 2 |
| McFarlane, SI | 1 |
| Keehn, CA | 1 |
| Pow-Sang, JM | 1 |
| Ahmad, N | 1 |
| Jarmuzewska, EA | 1 |
| Ghidoni, A | 1 |
| Mangoni, AA | 1 |
| Nuttall, FQ | 2 |
| Gannon, MC | 2 |
| Saeed, A | 1 |
| Jordan, K | 1 |
| Hoover, H | 1 |
| Malendowicz, LK | 1 |
| Neri, G | 1 |
| Nussdorfer, GG | 1 |
| Nowak, KW | 1 |
| Zyterska, A | 1 |
| Ziolkowska, A | 1 |
| Vedovato, M | 1 |
| Lepore, G | 1 |
| Coracina, A | 1 |
| Dodesini, AR | 1 |
| Jori, E | 1 |
| Tiengo, A | 1 |
| Del Prato, S | 1 |
| Trevisan, R | 1 |
| Zhang, A | 1 |
| Kohan, DE | 1 |
| Nelson, RD | 1 |
| Gonzalez, FJ | 1 |
| Yang, T | 1 |
| Kigoshi, T | 3 |
| Uehara, K | 1 |
| Furuya, K | 1 |
| Konishi, K | 1 |
| Fukuda, M | 1 |
| Nishizawa, M | 1 |
| Nakagawa, A | 1 |
| Nakano, S | 2 |
| Uchida, K | 3 |
| Berbarie, RF | 1 |
| Emmett, M | 1 |
| Breslau, NA | 1 |
| Rossing, K | 1 |
| Schjoedt, KJ | 1 |
| Jensen, BR | 1 |
| Parving, HH | 1 |
| Grönholm, T | 1 |
| Cheng, ZJ | 1 |
| Palojoki, E | 1 |
| Eriksson, A | 1 |
| Bäcklund, T | 1 |
| Vuolteenaho, O | 1 |
| Finckenberg, P | 1 |
| Laine, M | 1 |
| Mervaala, E | 1 |
| Tikkanen, I | 1 |
| Han, SY | 2 |
| Jee, YH | 2 |
| Han, KH | 2 |
| Han, JY | 2 |
| Kim, YS | 2 |
| Matos, JP | 1 |
| de Lourdes Rodrigues, M | 1 |
| Ismerim, VL | 1 |
| Boasquevisque, EM | 1 |
| Genelhu, V | 1 |
| Francischetti, EA | 1 |
| Advani, A | 1 |
| Taylor, R | 1 |
| Kyriakides, ZS | 1 |
| Kremastinos, DT | 1 |
| Raptis, AE | 1 |
| Johnston, N | 1 |
| Raptis, SA | 1 |
| Webb, DJ | 1 |
| Kyrzopoulos, S | 1 |
| Sbarouni, E | 1 |
| Kalantarinia, K | 1 |
| Okusa, MD | 1 |
| Jefic, D | 1 |
| Mohiuddin, N | 1 |
| Alsabbagh, R | 1 |
| Fadanelli, M | 1 |
| Steigerwalt, S | 1 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Kadomoto, Y | 1 |
| Tominaga, M | 1 |
| Jandeleit-Dahm, K | 1 |
| Cooper, ME | 2 |
| Shah, NC | 1 |
| Pringle, S | 1 |
| Stankovic, AR | 1 |
| Savoia, C | 1 |
| Schiffrin, EL | 1 |
| Sharman, DC | 1 |
| Morris, AD | 5 |
| Struthers, AD | 2 |
| Usukura, M | 1 |
| Oda, N | 1 |
| Takata, H | 1 |
| Yamamoto, Y | 1 |
| Yamagishi, M | 1 |
| Goenka, N | 1 |
| Kotonya, C | 1 |
| Penney, MD | 1 |
| Randeva, HS | 1 |
| O'Hare, JP | 1 |
| Shamkhlova, MSh | 1 |
| Trubitsyna, NP | 1 |
| Katsaia, GV | 1 |
| Goncharov, NP | 1 |
| Malysheva, NM | 1 |
| Il'in, AV | 1 |
| Nikankina, LV | 1 |
| Koshel', LV | 1 |
| Shestakova, MV | 1 |
| Swaminathan, K | 1 |
| George, J | 1 |
| Rajendra, NS | 1 |
| Griaznova, IM | 1 |
| Kniazev, IuA | 1 |
| Vtorova, VG | 1 |
| Bespalova, VA | 1 |
| Kirbasova, NP | 1 |
| Chan, JC | 1 |
| Nicholls, MG | 1 |
| Cheung, CK | 1 |
| Law, LK | 1 |
| Swaminathan, R | 1 |
| Cockram, CS | 1 |
| Salas-Ramírez, M | 1 |
| Ariza Andraca, R | 1 |
| Frati Munari, A | 1 |
| Muñoz, H | 1 |
| Altamirano, P | 1 |
| Ciavarella, A | 1 |
| Mustacchio, A | 1 |
| Ricci, C | 1 |
| Capelli, M | 1 |
| Vannini, P | 1 |
| Petrie, JR | 3 |
| Ueda, S | 2 |
| Connell, JM | 2 |
| Elliott, HL | 3 |
| Small, M | 3 |
| Donnelly, R | 2 |
| Grunenberger, F | 1 |
| Beretta-Piccoli, C | 1 |
| Elshater-Zanetti, F | 1 |
| Shaw, S | 1 |
| Cusi, D | 1 |
| Weidmann, P | 2 |
| Porzano, AM | 1 |
| Baldoncini, R | 1 |
| De Siati, L | 1 |
| Coassin, S | 1 |
| Desideri, G | 1 |
| Ferri, C | 1 |
| Laurenti, O | 1 |
| De Mattia, G | 1 |
| Santucci, A | 1 |
| Balsano, F | 1 |
| Kim, HJ | 2 |
| Ahn, YH | 1 |
| Park, CH | 1 |
| Kang, CM | 1 |
| Park, HC | 1 |
| Bae, HY | 2 |
| Choi, SD | 1 |
| Shimada, T | 1 |
| Yasuda, K | 1 |
| Mori, A | 1 |
| Ni, H | 1 |
| Mercado-Asis, LB | 1 |
| Murase, H | 1 |
| Miura, K | 1 |
| Tait, JF | 1 |
| Tait, SA | 1 |
| De'Oliveira, JM | 2 |
| Price, DA | 2 |
| Allan, DR | 1 |
| McKnight, JA | 2 |
| Williams, GH | 2 |
| Minamisawa, K | 1 |
| Hilditch, TE | 1 |
| McConnell, J | 1 |
| Hidaka, S | 1 |
| Kaneko, O | 1 |
| Shirai, M | 1 |
| Kojima, K | 1 |
| Igarashi, Y | 1 |
| Oda, K | 1 |
| Chimata, M | 1 |
| Nakamura, K | 1 |
| Nagase, M | 1 |
| Hishiki, S | 1 |
| Tochikubo, O | 1 |
| Miyajima, E | 1 |
| Ishii, M | 1 |
| Laederach-Hofmann, K | 1 |
| Ferrari, P | 1 |
| Yano, Y | 1 |
| Gabazza, EC | 1 |
| Katsuki, A | 1 |
| Furuta, M | 1 |
| Tanaka, T | 1 |
| Araki-Sasaki, R | 1 |
| Hori, Y | 1 |
| Sumida, Y | 1 |
| Adachi, Y | 1 |
| Houlihan, CA | 1 |
| Allen, TJ | 1 |
| Baxter, AL | 1 |
| Panangiotopoulos, S | 1 |
| Casley, DJ | 1 |
| Nannipieri, M | 1 |
| Seghieri, G | 1 |
| Catalano, C | 1 |
| Prontera, T | 1 |
| Baldi, S | 1 |
| Ferrannini, E | 1 |
| Resnick, LM | 1 |
| Sheridan, B | 1 |
| Roberts, G | 1 |
| Atkinson, AB | 1 |
| Iwasaki, R | 2 |
| Kaneko, M | 1 |
| Azukizawa, S | 1 |
| Morimoto, S | 2 |
| Ferriss, JB | 1 |
| Zanella, MT | 1 |
| Salgado, BJ | 1 |
| Kohlmann, O | 1 |
| Ribeiro, AB | 1 |
| Ueda, Y | 1 |
| Aoi, W | 1 |
| Yamachika, S | 1 |
| Shikaya, T | 1 |
| Tuck, M | 1 |
| Corry, D | 1 |
| Trujillo, A | 1 |
| Kokot, F | 2 |
| Duława, J | 2 |
| Bar, A | 1 |
| Klin, M | 1 |
| Grzeszczak, W | 2 |
| Darocha, Z | 1 |
| Koev, D | 1 |
| Zacharieva, S | 1 |
| Andonova, K | 1 |
| Yaginuma, K | 1 |
| Wiecek, A | 1 |
| Baba, T | 1 |
| Murabayashi, S | 1 |
| Ishizaki, T | 1 |
| Ido, Y | 1 |
| Aoyagi, K | 1 |
| Takebe, K | 1 |
| Jungmann, E | 1 |
| Wirth, K | 1 |
| Rosak, C | 1 |
| Althoff, PH | 1 |
| Pagano, G | 1 |
| Dal Molin, V | 1 |
| Bozzo, C | 1 |
| Carta, Q | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: The GOLD-Study"[NCT02770885] | Phase 2 | 50 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| "Effects of GLP-1 Analogues on Fluid Intake in Healthy Volunteers - The GATE-Study"[NCT03141632] | Phase 2 | 17 participants (Actual) | Interventional | 2016-10-17 | Completed | ||
| A Study of a 10-days Fenofibrate Treatment, or Until Discharge From Hospital, Among COVID-19 Infected Patients Requiring Hospitalization[NCT04661930] | Phase 3 | 55 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Time of Recovery and Prognostic Factors of COVID-19 Pneumonia[NCT04324684] | 198 participants (Actual) | Observational | 2020-03-31 | Completed | |||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19[NCT05736900] | 200 participants (Actual) | Interventional | 2020-09-10 | Completed | |||
| Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study.[NCT04480034] | 1,600 participants (Anticipated) | Observational | 2020-07-15 | Recruiting | |||
| The Role of Aldosterone in Diabetes Related Vascular Disease, a New Therapeutic Target?[NCT03017703] | 27 participants (Actual) | Interventional | 2016-12-01 | Completed | |||
| Investigating the Effect of Renin-Angiotensin System Inhibitors in Addition to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Prospective Open-label Study[NCT04707508] | Phase 4 | 203 participants (Actual) | Interventional | 2017-12-01 | Completed | ||
| Southern Danish Hypertension and Diabetes Study (SDHDS) With Amiloride[NCT02122731] | Phase 4 | 80 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequa[NCT01096667] | Phase 2 | 194 participants (Actual) | Interventional | 2010-05-17 | Completed | ||
| A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients[NCT04515095] | 30 participants (Actual) | Interventional | 2020-08-16 | Completed | |||
| Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study[NCT03917758] | 30 participants (Anticipated) | Interventional | 2018-10-10 | Recruiting | |||
| Disparities in CHD in the Jackson Heart Study[NCT00415415] | 5,302 participants | Observational | 2000-09-30 | Completed | |||
| Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome[NCT00666848] | Phase 4 | 24 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Genetic Based Analysis of Identifying Predictors of Blood Pressure Response in Hypertensive Patients After Renal Denervation[NCT04321044] | 300 participants (Actual) | Interventional | 2019-01-01 | Active, not recruiting | |||
| An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus[NCT00660309] | Phase 4 | 45 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| The Effect of Ingestion of Foods on the Plasma Glucose and Insulin Response in Subjects With Type 2 Diabetes: Protein, Amino Acids & Insulin & Glucagon Secretion in Humans[NCT01471509] | 300 participants (Anticipated) | Interventional | 1982-08-31 | Suspended (stopped due to Lack of funding) | |||
| EDUCATION TO DECREASE IN SODIUM INTAKE IN UNIVERSITY STUDENTS EVALUATED WITH 24 HOUR URINARY SODIUM EXCRETION: RANDOMIZED CONTROLLED TRIAL[NCT04894344] | 114 participants (Anticipated) | Interventional | 2020-10-28 | Recruiting | |||
| Association of BsmI Polymorphisms in Vitamin D Receptor Gene With Diabetic Kidney Disease[NCT03621384] | 93 participants (Actual) | Observational | 2014-11-30 | Completed | |||
| Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria[NCT00320879] | Phase 4 | 52 participants | Interventional | 2003-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM). (NCT01096667)
Timeframe: 24 hours
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 136.11 |
| Ertugliflozin 1 mg | 133.13 |
| Ertugliflozin 5 mg | 135.08 |
| Ertugliflozin 25 mg | 135.59 |
| HCTZ 12.5mg | 139.55 |
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as >20 hours and <28 hours). (NCT01096667)
Timeframe: 24 hours
| Intervention | grams/day (Mean) |
|---|---|
| Placebo | 13.35 |
| Ertugliflozin 1 mg | 9.97 |
| Ertugliflozin 5 mg | 8.04 |
| Ertugliflozin 25 mg | 17.56 |
| HCTZ 12.5mg | 6.96 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 169.47 |
| Ertugliflozin 1 mg | 158.38 |
| Ertugliflozin 5 mg | 158.29 |
| Ertugliflozin 25 mg | 172.03 |
| HCTZ 12.5mg | 156.87 |
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures. (NCT01096667)
Timeframe: Baseline
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 84.89 |
| Ertugliflozin 1 mg | 83.08 |
| Ertugliflozin 5 mg | 83.79 |
| Ertugliflozin 25 mg | 83.89 |
| HCTZ 12.5mg | 84.72 |
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures. (NCT01096667)
Timeframe: Baseline
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 77.07 |
| Ertugliflozin 1 mg | 78.73 |
| Ertugliflozin 5 mg | 77.30 |
| Ertugliflozin 25 mg | 75.63 |
| HCTZ 12.5mg | 77.97 |
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures. (NCT01096667)
Timeframe: Baseline
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 135.17 |
| Ertugliflozin 1 mg | 134.23 |
| Ertugliflozin 5 mg | 137.31 |
| Ertugliflozin 25 mg | 135.25 |
| HCTZ 12.5mg | 138.07 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline and Week 2
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -5.44 |
| Ertugliflozin 1 mg | -10.98 |
| Ertugliflozin 5 mg | -22.45 |
| Ertugliflozin 25 mg | -32.03 |
| HCTZ 12.5mg | 3.21 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 4.39 |
| Ertugliflozin 1 mg | -13.70 |
| Ertugliflozin 5 mg | -30.41 |
| Ertugliflozin 25 mg | -31.03 |
| HCTZ 12.5mg | 3.79 |
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.30 |
| Ertugliflozin 1 mg | -0.90 |
| Ertugliflozin 5 mg | -0.75 |
| Ertugliflozin 25 mg | -2.71 |
| HCTZ 12.5mg | -2.54 |
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Placebo | 2.34 |
| Ertugliflozin 1 mg | -1.86 |
| Ertugliflozin 5 mg | 1.22 |
| Ertugliflozin 25 mg | -1.51 |
| HCTZ 12.5mg | -0.99 |
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 1.24 |
| Ertugliflozin 1 mg | -2.77 |
| Ertugliflozin 5 mg | -5.92 |
| Ertugliflozin 25 mg | -4.96 |
| HCTZ 12.5mg | -3.13 |
Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.77 |
| Ertugliflozin 1 mg | -1.89 |
| Ertugliflozin 5 mg | -2.34 |
| Ertugliflozin 25 mg | -1.50 |
| HCTZ 12.5mg | -1.42 |
Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | Beats per minute (Least Squares Mean) |
|---|---|
| Placebo | 1.00 |
| Ertugliflozin 1 mg | -1.22 |
| Ertugliflozin 5 mg | 1.07 |
| Ertugliflozin 25 mg | -1.39 |
| HCTZ 12.5mg | -0.56 |
Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF). (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.26 |
| Ertugliflozin 1 mg | -2.71 |
| Ertugliflozin 5 mg | -3.73 |
| Ertugliflozin 25 mg | -3.42 |
| HCTZ 12.5mg | -2.95 |
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as >20 hours and <28 hours). In the case of missing data, LOCF. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | grams/day (Least Squares Mean) |
|---|---|
| Placebo | 4.15 |
| Ertugliflozin 1 mg | 46.33 |
| Ertugliflozin 5 mg | 64.54 |
| Ertugliflozin 25 mg | 74.49 |
| HCTZ 12.5mg | -0.48 |
Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.87 |
| Ertugliflozin 1 mg | -2.12 |
| Ertugliflozin 5 mg | -1.88 |
| Ertugliflozin 25 mg | -1.77 |
| HCTZ 12.5mg | -1.69 |
Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | Beats per minute (Least Squares Mean) |
|---|---|
| Placebo | 1.58 |
| Ertugliflozin 1 mg | -1.80 |
| Ertugliflozin 5 mg | 1.10 |
| Ertugliflozin 25 mg | -1.07 |
| HCTZ 12.5mg | -0.06 |
Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.82 |
| Ertugliflozin 1 mg | -2.88 |
| Ertugliflozin 5 mg | -3.61 |
| Ertugliflozin 25 mg | -4.17 |
| HCTZ 12.5mg | -3.10 |
Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 1.02 |
| Ertugliflozin 1 mg | -1.48 |
| Ertugliflozin 5 mg | -2.52 |
| Ertugliflozin 25 mg | -0.84 |
| HCTZ 12.5mg | -0.55 |
Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | Beats per minute (Least Squares Mean) |
|---|---|
| Placebo | -0.18 |
| Ertugliflozin 1 mg | -0.15 |
| Ertugliflozin 5 mg | 1.43 |
| Ertugliflozin 25 mg | -1.99 |
| HCTZ 12.5mg | -1.24 |
Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | -0.29 |
| Ertugliflozin 1 mg | -2.48 |
| Ertugliflozin 5 mg | -3.47 |
| Ertugliflozin 25 mg | -2.31 |
| HCTZ 12.5mg | -2.30 |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE. (NCT01096667)
Timeframe: Up to 28 days (treatment period)
| Intervention | Participants (Number) |
|---|---|
| Placebo | 0 |
| Ertugliflozin 1 mg | 0 |
| Ertugliflozin 5 mg | 0 |
| Ertugliflozin 25 mg | 1 |
| HCTZ 12.5mg | 0 |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. (NCT01096667)
Timeframe: Up to 63 days (including run-in, treatment period, and follow-up)
| Intervention | Participants (Number) |
|---|---|
| Placebo | 9 |
| Ertugliflozin 1 mg | 8 |
| Ertugliflozin 5 mg | 15 |
| Ertugliflozin 25 mg | 12 |
| HCTZ 12.5mg | 10 |
Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: up to 24 hours
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| 24-hr | Daytime | Nighttime | |
| Ertugliflozin 1 mg | 78.67 | 81.77 | 72.05 |
| Ertugliflozin 25 mg | 80.36 | 83.59 | 73.28 |
| Ertugliflozin 5 mg | 80.18 | 83.47 | 73.05 |
| HCTZ 12.5mg | 82.66 | 85.87 | 75.76 |
| Placebo | 81.89 | 85.32 | 74.24 |
Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: up to 24 hours
| Intervention | beats per minute (Mean) | ||
|---|---|---|---|
| 24-hr | Daytime | Nighttime | |
| Ertugliflozin 1 mg | 80.74 | 83.74 | 74.44 |
| Ertugliflozin 25 mg | 79.41 | 82.18 | 73.49 |
| Ertugliflozin 5 mg | 79.68 | 82.71 | 73.16 |
| HCTZ 12.5mg | 79.08 | 81.95 | 73.03 |
| Placebo | 81.11 | 84.43 | 74.05 |
Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Daytime: 16 hours; Nighttime: 8 hours
| Intervention | mmHg (Mean) | |
|---|---|---|
| Daytime | Nighttime | |
| Ertugliflozin 1 mg | 136.85 | 125.15 |
| Ertugliflozin 25 mg | 139.56 | 127.13 |
| Ertugliflozin 5 mg | 138.89 | 126.37 |
| HCTZ 12.5mg | 143.32 | 131.68 |
| Placebo | 139.95 | 127.54 |
The change in mean arterial pressure (MAP) in response to placebo or enalapril after pretreatment with 5 days of placebo (NCT00666848)
Timeframe: just prior to drug administration and 8 hours after drug administration
| Intervention | mmHg (Mean) |
|---|---|
| 2 (Enalapril 5mg) | -0.9 |
| 1 (Placebo) | 2.7 |
| 3 (Enalapril 10mg) | -7.9 |
Mean change in mean arterial pressure in response to placebo or enalapril in the presence of 5 days of sitagliptin 100mg/day (NCT00666848)
Timeframe: just prior to drug administration and 8 hours following treatment
| Intervention | mmHg (Mean) |
|---|---|
| 2 (Enalapril 5mg) | -5.7 |
| 1 (Placebo) | -2.3 |
| 3 (Enalapril 10mg) | -0.9 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~The measure of the single dose effect (SDE) for aliskiren and irbesartan was calculated as Day 2 peak - Day 2 baseline GFR. Baseline GFR was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak GFR was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 10.52 |
| Irbesartan | 10.16 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~The measure of the single dose effect (SDE) for captopril was calculated as Day 1 peak - Day 1 baseline GFR. Baseline GFR was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak GFR was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 1: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 11.29 |
| Irbesartan | 7.41 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~The measure of the single dose effect (SDE) for aliskiren and irbesartan was calculated as Day 2 peak - Day 2 baseline RPF. Baseline RPF was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak RPF was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 37.18 |
| Irbesartan | 35.88 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~The measure of the single dose effect (SDE) for captopril was calculated as Day 1 peak - Day 1 baseline RPF. Baseline RPF was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak RPF was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 1: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 43.32 |
| Irbesartan | 40.13 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~This maximum multiple dose effect (MDE_Max) was calculated as Day 15 peak - Day 2 baseline GFR. Baseline GFR was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak GFR was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and Day 15: 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 8.69 |
| Irbesartan | 2.96 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~This maximum multiple dose effect (MDE_Max) was calculated as Day 15 peak - Day 2 baseline. Baseline RPF was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak RPF was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and Day 15: 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 24.62 |
| Irbesartan | 24.22 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~This multiple dose effect at steady state (MDE_SS) was calculated as Day 15 baseline - Day 2 baseline GFR. Baseline GFR was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values." (NCT00660309)
Timeframe: Day 2 and Day 15 at Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) .
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 1.05 |
| Irbesartan | -5.67 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~This multiple dose effect at steady state (MDE_SS) was calculated as Day 15 baseline - Day 2 baseline. Baseline RPF was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values." (NCT00660309)
Timeframe: Day 2 and Day 15 at Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) .
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | -5.67 |
| Irbesartan | -13.08 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) was calculated as Day 15 peak - Day 2 peak GFR. Peak GFR was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2 and Day 15: 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | -1.71 |
| Irbesartan | -8.68 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) was calculated as Day 15 peak - Day 2 peak. Peak RPF was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2 and Day 15: 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | -12.74 |
| Irbesartan | -14.67 |
"Retinal blood flow was assessed using the laser Doppler technique. The blood flow in the superior temporal retinal artery in one of the eyes of each study participant was determined.~The Single dose effect of aliskiren or irbesartan was measured as the change/difference between Day 2 and baseline measurements.~The Multiple dose effect of aliskiren or irbesartan wsas measured as the change/difference between Day 15 and Day 2 measurements" (NCT00660309)
Timeframe: Baseline (Day 1), Day 2 and Day 15.
| Intervention | µL/min (Mean) | |
|---|---|---|
| Single dose effect [N=13, 13] | Multiple dose effect [N=13, 11] | |
| Aliskiren | -0.32 | 0.29 |
| Irbesartan | 0.43 | 0.35 |
"The following angiotensin I effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 19] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 18] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 2.20 | 0.14 | 0.24 | 0.14 | 1.06 |
| Irbesartan | 1.54 | 0.83 | 2.67 | 2.21 | 2.71 |
"The following angiotensin II effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 19] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 18] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 0.31 | 0.26 | 0.43 | 0.17 | 0.69 |
| Irbesartan | 0.34 | 1.23 | 4.05 | 3.05 | 2.49 |
"The following plasma pro-renin concentration effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 20] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 19] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 0.97 | 0.93 | 1.07 | 1.10 | 1.17 |
| Irbesartan | 1.01 | 0.96 | 1.20 | 1.13 | 1.18 |
"PRA was measured by the trapping method and the following effects assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 baseline / Day 2 baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 20] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 18] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 1.47 | 0.09 | 0.12 | 0.07 | 0.95 |
| Irbesartan | 1.19 | 1.30 | 3.79 | 3.28 | 2.67 |
"The following plasma renin concentration effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 20] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 19] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 1.18 | 2.53 | 4.41 | 4.81 | 1.93 |
| Irbesartan | 0.92 | 1.04 | 2.35 | 2.06 | 1.91 |
"The following serum aldosterone effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 20] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N= 21, 18] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 0.58 | 0.66 | 0.81 | 0.60 | 0.93 |
| Irbesartan | 0.75 | 0.65 | 0.82 | 0.64 | 1.02 |
23 reviews available for aldosterone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Nonsteroidal mineralcorticoid receptor antagonists: Novel therapeutic implication in the management of patients with type 2 diabetes.
Topics: Adipose Tissue, Brown; Aldosterone; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Mineraloc | 2021 |
[Conn's syndrome-Frequent and still too rarely diagnosed to underdiagnosed].
Topics: Adrenalectomy; Aldosterone; Diabetes Mellitus, Type 2; Humans; Hyperaldosteronism; Hypertension; Ren | 2022 |
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hyperkalemia; Inflammation; Mineralocortic | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effects of Vitamin D on Cardiovascular Risk and Oxidative Stress.
Topics: Aldosterone; Calcitriol; Calcium; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heart | 2023 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Mitigating risk of aldosterone in diabetic kidney disease.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hy | 2020 |
Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease.
Topics: Aldosterone; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 2021 |
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Topics: Adult; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; | 2019 |
Effects of aldosterone on insulin sensitivity and secretion.
Topics: Aldosterone; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistanc | 2014 |
Aldosterone and type 2 diabetes mellitus.
Topics: Aldosterone; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Insulin; Potassium; Renin-An | 2016 |
Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Chymases; Diabetes Mellitus, Type 2; | 2010 |
Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Human | 2013 |
The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Magnesium; Mineralocorticoid | 2002 |
Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Renin | 2003 |
The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascu | 2006 |
Hypertension and diabetes: role of the renin-angiotensin system.
Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Diabetes Mell | 2006 |
Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2006 |
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.
Topics: Aldosterone; Angiotensin II; Cell Adhesion Molecules; Cytokines; Diabetes Complications; Diabetes Me | 2007 |
[Calcitonin gene-related peptide (CGRP): a vasodilator neuropeptide with many potential applications].
Topics: Aldosterone; Atrial Natriuretic Factor; Calcitonin Gene-Related Peptide; Cardiovascular Diseases; Di | 1993 |
Insulin, the renin-angiotensin-aldosterone system and blood pressure.
Topics: Adult; Aldosterone; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Insulin; Racial Groups; Renin | 1997 |
Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hypertension and related metabolic disorders.
Topics: Aldosterone; Blood Glucose; Blood Pressure; Calcium; Calcium Channel Blockers; Cardiomegaly; Diabete | 1992 |
The causes of raised blood pressure in insulin-dependent and non-insulin-dependent diabetes.
Topics: Aldosterone; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopat | 1991 |
44 trials available for aldosterone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
Topics: Aldosterone; Angiotensin II; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide 1 | 2022 |
Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
Topics: Aldosterone; Angiotensin II; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide 1 | 2022 |
Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
Topics: Aldosterone; Angiotensin II; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide 1 | 2022 |
Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
Topics: Aldosterone; Angiotensin II; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide 1 | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Renin; Sodium | 2022 |
Changes of aldosterone levels in patients with type 2 diabetes complicated by moderate to severe obstructive sleep apnea-hypopnea syndrome before and after treatment with continuous positive airway pressure.
Topics: Aldosterone; Angiotensin II; Case-Control Studies; Continuous Positive Airway Pressure; Diabetes Mel | 2019 |
Effect of angiotensin II receptor blocker and salt supplementation on short-term blood pressure variability in type 2 diabetes.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Blood Pressure; Cross-Over Studies; D | 2020 |
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzh | 2020 |
Aldosterone Induces Vasoconstriction in Individuals with Type 2 Diabetes: Effect of Acute Antioxidant Administration.
Topics: Acetylcysteine; Adult; Aldosterone; Antioxidants; Case-Control Studies; Denmark; Diabetes Mellitus, | 2021 |
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.
Topics: Adult; Aged; Albumins; Albuminuria; Aldosterone; Amides; Antihypertensive Agents; Arterial Pressure; | 2013 |
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2013 |
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
Topics: Adult; Aged; Albumins; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitori | 2013 |
25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2013 |
Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
Topics: Adult; Aged; Albuminuria; Aldosterone; Asian People; Blood Pressure; Diabetes Mellitus, Type 2; Diab | 2015 |
Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension.
Topics: Aldosterone; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambu | 2015 |
Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes.
Topics: Adult; Aldosterone; Black or African American; Blood Pressure; C-Reactive Protein; Diabetes Mellitus | 2009 |
Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Aldosterone; Amlodipine; Arteries; Calcium Channel Blockers; Calc | 2009 |
The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus.
Topics: Aldosterone; Amine Oxidase (Copper-Containing); Atrial Natriuretic Factor; Cross-Over Studies; Diabe | 2010 |
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Diabete | 2010 |
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; B | 2011 |
Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
Topics: Aldosterone; Amides; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fem | 2012 |
Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibito | 2011 |
Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Albuminuria; Aldosterone; Amides; Amlodipine; Angiotensin | 2012 |
Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes: a duplex Doppler sonography study.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diabetes Me | 2003 |
Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diab | 2003 |
The metabolic response of subjects with type 2 diabetes to a high-protein, weight-maintenance diet.
Topics: Aldosterone; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cross-Over Studies; Diabetes Mellitus, | 2003 |
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance.
Topics: Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Die | 2004 |
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance.
Topics: Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Die | 2004 |
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance.
Topics: Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Die | 2004 |
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance.
Topics: Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Die | 2004 |
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood P | 2005 |
Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2005 |
The metabolic response to a high-protein, low-carbohydrate diet in men with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Aldosterone; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Diet | 2006 |
Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2006 |
Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus.
Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; B | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2007 |
Thiazolidinediones and the renal and hormonal response to water immersion-induced volume expansion in type 2 diabetes mellitus.
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Blood Volume; Diabetes Mellitus, Type 2; Hom | 2008 |
Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles.
Topics: Aged; Aldosterone; Angiotensin II; Blood Glucose; Blood Pressure; Body Mass Index; Cross-Over Studie | 2008 |
Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM.
Topics: Albuminuria; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Blood P | 1995 |
Enhanced pressor responsiveness to norepinephrine in type II diabetes. Effect of ACE inhibition.
Topics: Adult; Aldosterone; Blood Pressure; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; | 1994 |
Pressor and subpressor doses of angiotensin II increase insulin sensitivity in NIDDM. Dissociation of metabolic and blood pressure effects.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; C-Peptide; Cardiac Output; Cross-Over Stud | 1994 |
Effects of short-time insulin suppression on renal sodium excretion in type II diabetic hypertensives.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Diabetes Mellitus, Type 2; Diastole; | 1993 |
Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus.
Topics: Aged; Aldosterone; Angiotensin II; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Sodium-Restr | 1998 |
Do obesity and non-insulin dependent diabetes mellitus aggravate exercise-induced microproteinuria?
Topics: Adolescent; Adult; Albumins; Aldosterone; beta 2-Microglobulin; Catecholamines; Diabetes Mellitus, T | 1998 |
The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Female | 1999 |
Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; C | 2000 |
A low-sodium diet potentiates the effects of losartan in type 2 diabetes.
Topics: Albuminuria; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cr | 2002 |
Defective regulation and action of atrial natriuretic peptide in type 2 diabetes.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Glucose; Blood Volume; Body Mass Index; D | 2002 |
[Increased endogenous dopamine activity in diabetes mellitus. Inhibition of plasma renin activity, aldosterone and prolactin secretion].
Topics: Aged; Aldosterone; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dopamine; Humans; Hypertensi | 1986 |
Interference on metabolism induced by muzolimine and chlorthalidone in type II hypertensive diabetics.
Topics: Aldosterone; Blood Glucose; Blood Pressure; Carbohydrate Metabolism; Chlorthalidone; Clinical Trials | 1985 |
95 other studies available for aldosterone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Prevalence of primary aldosteronism in type 2 diabetes mellitus and hypertension: A prospective study from Western India.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Female; Humans; Hyperaldosteronism; Hypertension; Ind | 2022 |
Effects of tofogliflozin on adrenocorticotropic hormone, renin and aldosterone, and cortisol levels in elderly patients with diabetes mellitus: A retrospective study of a patient cohort.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glu | 2021 |
Screening for primary aldosteronism in the diabetic population: a cohort study.
Topics: Aldosterone; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hyperaldosteronism; Hypertension; Ma | 2023 |
Preoperative Plasma Aldosterone Predicts Complete Remission of Type 2 Diabetes after Bariatric Surgery.
Topics: Aldosterone; Bariatric Surgery; Diabetes Mellitus, Type 2; Gastrectomy; Gastric Bypass; Glycated Hem | 2022 |
Association of renin and aldosterone with glucose metabolism in a Western European population: the KORA F4/FF4 study.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin Resistance; Renin | 2022 |
Aldosterone-to-Renin Ratio Is Associated with Diabetic Nephropathy in Type 2 Diabetic Patients: A Single-Center Retrospective Study.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Male; Middle | 2022 |
The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex - a multicenter-study of 3566 Caucasian and Asian subjects.
Topics: Adenoma; Aldosterone; Diabetes Mellitus, Type 2; Female; Humans; Hydrocortisone; Hyperaldosteronism; | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
The mineralocorticoid receptor gene (NR3C2) is linked to and associated with polycystic ovarian syndrome in Italian families.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Female; Humans; Hyperandrogenism; Insulin Resistance; Minera | 2023 |
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosi | 2023 |
Association and progression of multi-morbidity with Chronic Kidney Disease stage 3a secondary to Type 2 Diabetes Mellitus, grouped by albuminuria status in the multi-ethnic population of Northwest London: A real-world study.
Topics: Albuminuria; Aldosterone; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypertension; London; Mi | 2023 |
Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mell | 2023 |
Decreased plasma aldosterone levels in patients with type 2diabetes mellitus: A possible pitfall in diagnosis of primary aldosteronism.
Topics: Adult; Aged; Aldosterone; Artifacts; Blood Chemical Analysis; Blood Pressure; Case-Control Studies; | 2019 |
Mineralocorticoids, glucose homeostasis and type 2 diabetes mellitus: The Henan Rural Cohort study.
Topics: Aged; Aldosterone; Biomarkers; Blood Glucose; Case-Control Studies; China; Desoxycorticosterone; Dia | 2020 |
Lipoprotein insulin resistance score and branched-chain amino acids increase after adrenalectomy for unilateral aldosterone-producing adenoma: a preliminary study.
Topics: Adenoma; Adrenalectomy; Aldosterone; Amino Acids, Branched-Chain; Diabetes Mellitus, Type 2; Humans; | 2020 |
Determining the Prevalence of Primary Aldosteronism in Patients With New-Onset Type 2 Diabetes and Hypertension.
Topics: Aldosterone; Biomarkers; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypera | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
An evaluation of renin-angiotensin system markers in youth with type 2 diabetes and associations with renal outcomes.
Topics: Adolescent; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensinogen; Biomarkers; | 2020 |
The cytochrome 11B2 aldosterone synthase gene rs1799998 single nucleotide polymorphism determines elevated aldosterone, higher blood pressure, and reduced glomerular filtration, especially in diabetic female patients.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Case-Control Studies; Cytochrome P-450 CYP11B2; Diabetes M | 2020 |
Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study.
Topics: Aged; Aldosterone; Diabetes Mellitus, Type 2; Female; Humans; Hyperaldosteronism; Hypertension; Male | 2020 |
Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridin | 2021 |
Prevalence of primary aldosteronism among patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Blood Pressure; Cross-Sectional Studies; Diabetes Melli | 2017 |
Associations between glycaemic control and activation of the renin-angiotensin-aldosterone system in participants with type 2 diabetes mellitus and hypertension.
Topics: Aged; Aldosterone; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycat | 2018 |
Renin-Angiotensin-Aldosterone System, Glucose Metabolism and Incident Type 2 Diabetes Mellitus: MESA.
Topics: Aged; Aldosterone; Asian; Black or African American; Blood Glucose; Cohort Studies; Diabetes Mellitu | 2018 |
Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus.
Topics: Aged; Aldosterone; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male | 2019 |
Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D.
Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progressio | 2019 |
Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aldosterone; Biomarkers; Contrast Media; Diabetes Mellitus, Type 2; Echocar | 2013 |
Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; Asian People; Diabetes | 2013 |
Marine natural product des-O-methyllasiodiplodin effectively lowers the blood glucose level in db/db mice via ameliorating inflammation.
Topics: 3T3-L1 Cells; Aldosterone; Animals; Apocynaceae; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2 | 2013 |
Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin-angiotensin-aldosterone system.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2014 |
Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?
Topics: Aldosterone; Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fe | 2013 |
SGK1 is regulated by metabolic-related factors in 3T3-L1 adipocytes and overexpressed in the adipose tissue of subjects with obesity and diabetes.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Aldosterone; Animals; Diabetes Mellitus, Type 2; Humans; I | 2013 |
Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldosterone concentrations but is affected by ethnicity.
Topics: Adolescent; Adult; Aged; Aldosterone; Black People; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty | 2014 |
Akt-mediated cardioprotective effects of aldosterone in type 2 diabetic mice.
Topics: Aldosterone; Animals; Blood Glucose; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Type 2; Diet, High | 2014 |
Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Blood P | 2015 |
Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels.
Topics: Aged; Aged, 80 and over; Aldosterone; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, T | 2014 |
Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus.
Topics: Aldosterone; Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Collagen; Diabetes Me | 2015 |
Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up.
Topics: Aged; Aldosterone; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Echocardiography; | 2015 |
A cross-sectional study of the effects of β-blocker therapy on the interpretation of the aldosterone/renin ratio: can dosing regimen predict effect?
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Antihypertensive Agents; Cross-Sectional Studies; Di | 2016 |
Aldosterone, Renin, and Diabetes Mellitus in African Americans: The Jackson Heart Study.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Black or African American; Blood Pressure; Body Mass In | 2016 |
Altered relation of the renin-aldosterone system and vasoactive peptides in type 2 diabetes: The KORA F4 study.
Topics: Adrenomedullin; Adult; Aged; Aldosterone; Anthropometry; Biomarkers; Carotid Arteries; Carotid Intim | 2016 |
Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.
Topics: Adrenal Glands; Aldosterone; Animals; Blood Glucose; Body Weight; Cytochrome P-450 CYP11B2; Diabetes | 2016 |
Advanced glycation of high-density lipoprotein and the functionality of aldosterone release in type 2 diabetes.
Topics: Adrenal Cortex; Aged; Aldosterone; Cell Line; Diabetes Mellitus, Type 2; Female; Humans; Lipoprotein | 2017 |
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Topics: Aldosterone; Animals; Benzhydryl Compounds; Chymosin; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2016 |
Elevated Steroid Hormone Production in the db/db Mouse Model of Obesity and Type 2 Diabetes.
Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Corticosterone; Desoxycorticosterone; Diabetes Mellit | 2017 |
Serum potassium is a predictor of incident diabetes in African Americans with normal aldosterone: the Jackson Heart Study.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Black or African American; Diabetes Mellitus, Type 2; F | 2017 |
Increased aldosterone levels in a model of type 2 diabetes mellitus.
Topics: Actins; Albuminuria; Aldosterone; Animals; Blood Pressure; Cytochrome P-450 CYP11B2; Diabetes Mellit | 2009 |
Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients.
Topics: Adult; Aged; Aldosterone; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2008 |
Prediabetic and diabetic in vivo modification of circulating low-density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion.
Topics: Adrenal Cortex; Adult; Aldosterone; Cell Line; Diabetes Mellitus, Type 2; Female; Glucose Tolerance | 2009 |
The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways.
Topics: Aldosterone; Animals; Cyclic GMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug E | 2009 |
Hyperaldosteronism and altered expression of an SGK1-dependent sodium transporter in ZDF rats leads to salt dependence of blood pressure.
Topics: Aldosterone; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Disease Models, Animal; Epithelial | 2010 |
Cardiovascular correlates of insulin resistance in normotensive and hypertensive African Americans.
Topics: Adolescent; Adult; Aldosterone; Black or African American; Blood Glucose; Blood Pressure; Cardiac Ou | 2011 |
[Variants of surgical management for severe arterial hypertension combined with type 2 diabetes mellitus].
Topics: Adult; Aged; Aldosterone; Atherosclerosis; Cadaver; Diabetes Mellitus, Type 2; Female; Follow-Up Stu | 2010 |
Relationships between renin, aldosterone, and 24-hour ambulatory blood pressure in obese adolescents.
Topics: Adolescent; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Chi | 2011 |
Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men.
Topics: Aldosterone; Blood Pressure; Diabetes Mellitus, Type 2; Gene Frequency; Genotype; Hemodynamics; Huma | 2011 |
Combined aldosterone and cortisol secretion by adrenal incidentaloma.
Topics: Adrenal Gland Neoplasms; Aged; Aldosterone; Cushing Syndrome; Diabetes Mellitus, Type 2; Female; Hum | 2012 |
Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Cell Line; Cell Proliferation; Cholesterol Esters; Diab | 2012 |
Leptin and aldosterone in sympathetic activity in resistant hypertension with or without type 2 diabetes.
Topics: Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; | 2012 |
Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat.
Topics: Aldosterone; Animals; Arrestins; beta-Arrestin 2; beta-Arrestins; Blood Glucose; CSK Tyrosine-Protei | 2013 |
Protective effects of captopril in diabetic rats exposed to ischemia/reperfusion renal injury.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Caspase 3; Creatinine; Di | 2013 |
Pathologic quiz case: a 57-year-old man with hypertension and hypokalemia.
Topics: Adenocarcinoma, Clear Cell; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Aldoste | 2003 |
Relative preservation of the renin-angiotensin-aldosterone system response to active orthostatism in type 2 diabetic patients with autonomic neuropathy and postural hypotension.
Topics: Aldosterone; Autonomic Nervous System Diseases; Blood Pressure; Catecholamines; Diabetes Mellitus, T | 2003 |
Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Animals; Corticosterone; Diabetes Mellitus, Experimental; | 2003 |
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
Topics: Aldosterone; Animals; Biological Transport; Body Weight; Coloring Agents; Diabetes Mellitus, Type 2; | 2005 |
Relationship between impaired aldosterone response to adrenocorticotropic hormone and prevalence of hemodialysis in type 2 diabetic patients without azotemia.
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Diabetes Mellitus, Type 2; Female; Follow-Up Studie | 2005 |
Quiz page. Secondary hypertension with contralateral pheochromocytoma and aldosteronoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Aldosterone; Antihypertensive Agent | 2005 |
Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Glu | 2005 |
Role of aldosterone in diabetic nephropathy.
Topics: Albuminuria; Aldosterone; Animals; Cells, Cultured; Chemokine CCL2; Collagen; Connective Tissue Grow | 2005 |
Life-threatening hypokalaemia on a low-carbohydrate diet associated with previously undiagnosed primary hyperaldosteronism [corrected].
Topics: Aldosterone; Diabetes Mellitus, Type 2; Diet, Reducing; Dietary Carbohydrates; Humans; Hypoaldostero | 2005 |
Impaired effect of endothelin-1 on coronary artery stiffness in type 2 diabetes.
Topics: Aged; Aldosterone; Compliance; Coronary Vessels; Diabetes Mellitus, Type 2; Endothelin Receptor Anta | 2006 |
The prevalence of primary aldosteronism in diabetic patients.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperaldosteronism; H | 2006 |
Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Collagen Type IV; Connective Tissue Gro | 2006 |
Prorenin and angiotensin-dependent renal vasoconstriction in type 1 and type 2 diabetes.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Diabetes Mellitus, Type 1; | 2006 |
[The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Di | 2008 |
[Osmotic homeostatic characteristics of pregnant women with diabetes mellitus and of their fetuses].
Topics: Aldosterone; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diab | 1984 |
Effect of plasma volume expansion on auricular natriuretic peptide in non-dependent insulin diabetic patients with autonomic neuropathy.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Autonomic Nervous System Diseases; Diabetes Mellitus, | 1995 |
Acute sodium loading in patients with uncomplicated diabetes mellitus: renal and hormonal effects.
Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Diabetes Mellitus; Diabet | 1994 |
Impaired homeostatic mechanism of potassium handling after acute oral potassium load in diabetes mellitus.
Topics: Adult; Aged; Aldosterone; Diabetes Mellitus, Type 2; Homeostasis; Humans; Kidney Tubules; Male; Midd | 1993 |
Aldosterone binding to mineralocorticoid receptors of mononuclear leukocytes in diabetic subjects.
Topics: Adult; Aged; Aldosterone; Binding Sites; Corticosterone; Desoxycorticosterone; Diabetes Mellitus; Di | 1993 |
Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitu | 1997 |
Circadian variation of urinary microalbumin excretion and ambulatory blood pressure in patients with essential hypertension.
Topics: Adult; Aged; Albuminuria; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Blood Pressure Mon | 1998 |
Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus.
Topics: Adult; Aged; Aldosterone; Blood Glucose; Blood Pressure; Blood Volume; Diabetes Mellitus, Type 2; Ep | 1999 |
Plasma levels of natriuretic peptides are correlated with renin activity in normotensive type 2 diabetic patients.
Topics: Aldosterone; Atrial Natriuretic Factor; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged | 2000 |
Heterogeneous changes of serum potassium levels in NIDDM patients on oral glucose load.
Topics: Administration, Oral; Adult; Aldosterone; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolera | 1992 |
Basal and stimulated plasma atrial natriuretic factor in type 2 diabetes.
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Fe | 1991 |
Lack of enhanced responsiveness of plasma 18-hydroxycorticosterone and aldosterone to adrenocorticotropin as well as to angiotensin-II during moderate sodium depletion in type II diabetic subjects with normoreninemia.
Topics: 18-Hydroxycorticosterone; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Aged; Aldoste | 1991 |
Angiotensin-converting enzyme (ACE) inhibition. Therapeutic option for diabetic hypertensive patients.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Enalapril; Female; Humans; Hypertension; Male; Middle | 1990 |
Beneficial effects of angiotensin-converting enzyme inhibitor on renal function and glucose homeostasis in diabetics with hypertension.
Topics: Aged; Aldosterone; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 1990 |
Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Diet, Sodium-Re | 1990 |
Water-immersion-induced alterations of atrial natriuretic peptide, plasma renin activity, aldosterone and vasopressin in diabetic patients.
Topics: Adult; Aldosterone; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Pressure; Diabetes Mellit | 1989 |
Plasma 18-hydroxycorticosterone and aldosterone responses to angiotensin II and corticotropin in diabetic patients with hyporeninemic and normoreninemic hypoaldosteronism.
Topics: 18-Hydroxycorticosterone; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Corticosterone; | 1989 |
Involvement of prostaglandins in the action of captopril in type II diabetic patients.
Topics: 6-Ketoprostaglandin F1 alpha; Aldosterone; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Din | 1989 |
[Studies on hypoaldosteronism associated with diabetes mellitus: response of plasma steroids to angiotensin II or ACTH administration].
Topics: 18-Hydroxycorticosterone; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Angiotensin II; Cor | 1986 |
[Effect of water immersion on plasma renin activity, vasopressin and aldosterone level in diabetics].
Topics: Aldosterone; Arginine Vasopressin; Blood Volume; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 1987 |
Renal kallikrein in diabetic patients with hypertension accompanied by nephropathy.
Topics: Adult; Aged; Aldosterone; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; | 1986 |